1. Scrip
  2. >>Business

IPO Update: Three More Biotechs Squeeze Through The Window

 
• By Mandy Jackson

What's the best metaphor for the past two weeks of US biotechnology initial public offerings? That would be a sharp intake of air through the teeth – the sound you make when you see someone do something really painful.

During the second and third weeks of May, three therapeutics developers squeezed through the IPO window, which isn't letting as many companies through as it did between 2013 and 2015. After setting terms at the low end of a single-digit stock price range, slashing proposed share prices, and adding warrants to slimmed down offerings, PhaseRx, Merus BV and Oncobiologics Inc. launched into the public market and provided an average loss of 3.4% as of May 20.

To be fair, the Cranbury, New Jersey-based biosimilar developer OncoBiologics was the only one out of the three to generate a negative return and the company has been trading on the Nasdaq since May

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Finance Watch: Funding Alternatives Become The Norm In Tough Public Markets

 
• By Mandy Jackson

Public Company Edition: With fewer follow-on offerings, drug developers are pursuing other options. Axsome accessed up to $570m in debt, Evolus obtained $250m in a new credit facility and Abeona raised $155m from a PRV sale, but Apimeds was able to execute a small $13.5m IPO.

iTeos/GSK To Terminate Collaboration After TIGIT Trials Flop

 
• By Alaric DeArment

Belrestotug is the latest anti-TIGIT candidate to fail to meet expectations. iTeos said it will pursue strategic alternatives.

‘Market Developments’ Persuade Galapagos To Rethink Spin-Off

 
• By Andrew McConaghie

CEO Paul Stoffels exits early to be succeeded by Henry Gosebruch, who will now consider ‘all options’ for the Belgian firm as it tries to claw back investor confidence.